We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Teams Up With BioTek, Expands Product Portfolio
Read MoreHide Full Article
Agilent Technologies, Inc. (A - Free Report) and BioTek Instruments recently teamed up to develop a new integrated solution that combines cellular metabolic analysis and imaging technologies.
Vermont-based, BioTek Instruments is a developer of microplate instrumentation and software.
The latest solution will be developed by integrating Agilent’s Seahorse XFe96 and XFe24 Analyzers with BioTek’s Cytation 1 Cell Imaging Multi-Mode Reader. It will enable improved comparison of XF data and embedment of images into WAVE software. Additionally, the solution will enhance the assay workflow and normalize XF measurements.
Seahorse XFe96 Analyzers and XFe24 Analyzers measure OCR and ECAR of live cells in 96 and 24 well plate format, respectively, where OCR and ECAR are the indicators of mitochondrial respiration and glycolysis.
Cytation 1 Cell Imaging Multi-Mode Reader provides quantitative phenotypic cellular information by combining fluorescence and high contrast brightfield imaging with conventional multi-mode detection.
The new solution is set to roll out in the United States and Europe in this month itself and the rest of the world by June 2018.
Shares of Agilent have underperformed the industry it belongs to over a year. The stock has returned 24.2% compared with the industry’s rally of 30.5%.
Deal Rationale
With the latest solution, researchers will be able a detailed cell analysis with XF data, and brightfield and fluorescence images and understand cellular metabolism better.
The latest move will expand Agilent’s cell analysis portfolio. This will also help to meet the growing demands in the field of cell analysis. Per a report form Markets and Markets, the global cell analysis market is expected to reach $26.0 billion by 2020, growing at a CAGR of 6.56% from 2015 to 2020.
We believe the company’s footprint will strengthen in various industries like life science, biotechnology and many more, courtesy of the move.
Agilent’s focus on innovation and efforts on aligning investments toward promising growth avenues along with innovative high-margin product launches are likely to diversify the company’s product portfolio.
The latest partnership helps the company to expand its product portfolio.
Further, it is evident from the company’s past records that strategic acquisitions and partnerships have played an important role in shaping its growth trajectory. The buyouts of AATI (March 2018), Luxcel Biosciences (January 2018), Cobalt Light Systems (July 2017), Multiplicom NV (January 2017), Seahorse Bioscience and iLab Solutions (2016) have expanded its product portfolio.
AATI deal will strengthen Agilent’s capillary electrophoresis solutions portfolio. The solutions of AATI are extensively used for medical and molecular diagnostics for both commercial and research purposes.
Luxcel Biosciences deal expands Agilent’s presence in the high-growth cell analysis market and provides a technology that targets important applications, namely cell metabolism, bioenergetics, drug toxicity, and hypoxia and oxidative stress.
Multiplicom deal expanded Agilent’s genetic testing technology and product offerings. The Cobalt deal strengthened the company’s presence in the high-growth Raman spectroscopy market. The iLab Solutions acquisition enabled the company to provide cloud-based laboratory management software.
Moreover, Seahorse Bioscience’s technology was a strategic fit for Agilent’s market-leading separations and mass spectrometry solutions, especially those that cater to metabolomics and disease research in pharma.
We believe its robust products will continue to drive the company’s top-line growth by performing well in the end markets. Last quarter, the company generated $1.21 revenues, which reflected 13.2% year over year growth.
Zacks Rank & Other Stocks to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy).
Investors interested in the broader technology sector can consider a few other top-ranked stocks like NVIDIA Corporation (NVDA - Free Report) , Micron Technology (MU - Free Report) and Fortive Corporation (FTV - Free Report) . While NVIDIA and Micron Technology sport a Zacks Rank #1 (Strong Buy), Fortive carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for NVIDIA, Micron Technology and Fortive is currently pegged at 10.25%, 10% and 9.64%, respectively.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Agilent Teams Up With BioTek, Expands Product Portfolio
Agilent Technologies, Inc. (A - Free Report) and BioTek Instruments recently teamed up to develop a new integrated solution that combines cellular metabolic analysis and imaging technologies.
Vermont-based, BioTek Instruments is a developer of microplate instrumentation and software.
The latest solution will be developed by integrating Agilent’s Seahorse XFe96 and XFe24 Analyzers with BioTek’s Cytation 1 Cell Imaging Multi-Mode Reader. It will enable improved comparison of XF data and embedment of images into WAVE software. Additionally, the solution will enhance the assay workflow and normalize XF measurements.
Seahorse XFe96 Analyzers and XFe24 Analyzers measure OCR and ECAR of live cells in 96 and 24 well plate format, respectively, where OCR and ECAR are the indicators of mitochondrial respiration and glycolysis.
Cytation 1 Cell Imaging Multi-Mode Reader provides quantitative phenotypic cellular information by combining fluorescence and high contrast brightfield imaging with conventional multi-mode detection.
The new solution is set to roll out in the United States and Europe in this month itself and the rest of the world by June 2018.
Shares of Agilent have underperformed the industry it belongs to over a year. The stock has returned 24.2% compared with the industry’s rally of 30.5%.
Deal Rationale
With the latest solution, researchers will be able a detailed cell analysis with XF data, and brightfield and fluorescence images and understand cellular metabolism better.
The latest move will expand Agilent’s cell analysis portfolio. This will also help to meet the growing demands in the field of cell analysis. Per a report form Markets and Markets, the global cell analysis market is expected to reach $26.0 billion by 2020, growing at a CAGR of 6.56% from 2015 to 2020.
We believe the company’s footprint will strengthen in various industries like life science, biotechnology and many more, courtesy of the move.
Strategic Partnership & Acquisition – Key Catalyst
Agilent’s focus on innovation and efforts on aligning investments toward promising growth avenues along with innovative high-margin product launches are likely to diversify the company’s product portfolio.
The latest partnership helps the company to expand its product portfolio.
Further, it is evident from the company’s past records that strategic acquisitions and partnerships have played an important role in shaping its growth trajectory. The buyouts of AATI (March 2018), Luxcel Biosciences (January 2018), Cobalt Light Systems (July 2017), Multiplicom NV (January 2017), Seahorse Bioscience and iLab Solutions (2016) have expanded its product portfolio.
AATI deal will strengthen Agilent’s capillary electrophoresis solutions portfolio. The solutions of AATI are extensively used for medical and molecular diagnostics for both commercial and research purposes.
Luxcel Biosciences deal expands Agilent’s presence in the high-growth cell analysis market and provides a technology that targets important applications, namely cell metabolism, bioenergetics, drug toxicity, and hypoxia and oxidative stress.
Multiplicom deal expanded Agilent’s genetic testing technology and product offerings. The Cobalt deal strengthened the company’s presence in the high-growth Raman spectroscopy market. The iLab Solutions acquisition enabled the company to provide cloud-based laboratory management software.
Moreover, Seahorse Bioscience’s technology was a strategic fit for Agilent’s market-leading separations and mass spectrometry solutions, especially those that cater to metabolomics and disease research in pharma.
We believe its robust products will continue to drive the company’s top-line growth by performing well in the end markets. Last quarter, the company generated $1.21 revenues, which reflected 13.2% year over year growth.
Zacks Rank & Other Stocks to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy).
Investors interested in the broader technology sector can consider a few other top-ranked stocks like NVIDIA Corporation (NVDA - Free Report) , Micron Technology (MU - Free Report) and Fortive Corporation (FTV - Free Report) . While NVIDIA and Micron Technology sport a Zacks Rank #1 (Strong Buy), Fortive carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for NVIDIA, Micron Technology and Fortive is currently pegged at 10.25%, 10% and 9.64%, respectively.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>